Article
No cross-resistance or selection of HIV-1 resistant mutants in vitro to the antiretroviral tripeptide glycyl-prolyl-glycine-amide.
Antiviral research - 1 Feb 2004
Andersson Elin, Horal Peter, Vahlne Anders, Svennerholm Bo
Abstract excerpt
The chemically modified tripeptide glycyl-prolyl-glycine-amide (GPG-NH(2)) inhibits replication of HIV-1 in vitro, probably by interfering with capsid formation. This study was aimed at determining cross-resistance between antiretroviral drugs and GPG-NH(2), and whether resistance to GPG-NH(2) can be induced in vitro. Fifty-five clinical HIV-1 isolates with different resistance-related mutations were tested for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.